Abstract: This invention provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's abnormality. This invention further provides a method of treating pain, particularly chronic pain, chronic inflammatory pain and arthritic pain, which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's pain.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF12 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF12 receptor and having a sequence identical to the sequence of the human SNORF12 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF12-f (ATCC Accession No. ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF12 receptor, wherein the human SNORF12 receptor comprises an amino acid sequence identical to the sequence of the human SNORF12 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF40 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF40 receptor and having a sequence identical to the sequence of the human SNORF40 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF40-f (ATCC Accession No.______ ). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF40 receptor, wherein the human SNORF40 receptor comprises an amino acid sequence identical to the sequence of the human SNORF40 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF4 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF4 receptor and having a sequence identical to the sequence of the human SNORF4 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF4-f (ATCC Accession No. ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF4 receptor, wherein the human SNORF4 receptor comprises an amino acid sequence identical to the sequence of the human SNORF4 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1C (Seq. I.D. No. 1).

Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF10 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF10 receptor and having a sequence identical to the sequence of the human SNORF10 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF10-f (ATCC Accession No. ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF10 receptor, wherein the human SNORF10 receptor comprises an amino acid sequence identical to the sequence of the human SNORF10 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1D (Seq. I.D. No. 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF66 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF66 receptor and having a sequence identical to the sequence of the human SNORF66 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF66-f (Patent Deposit Designation No. PTA______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF66 receptor, wherein the human SNORF66 receptor comprises an amino acid sequence identical to the sequence of the human SNORF66 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF36 receptors, purified mammalian SNORF36 receptors, vectors comprising nucleic acid encoding mammalian SNORF36 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF36 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF36 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF36 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF36 receptors, methods of isolating mammalian SNORF36 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF36 receptors, as well as methods of determining binding of compounds to mammalian SNORF36 receptors, methods of identifying agonists and antagonists of SNORF36 receptors, and agonists and antagonists so identified.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF11 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF11 receptor and having a sequence identical to the sequence of the human SNORF11 receptor-encoding nucleic acid contained in plasmid pEXJRHT3T7-hSNORF11-f (ATCC Accession No. ______ ) or (b) a nucleic acid encoding a rat SNORF11 receptor and having a sequence identical to the sequence of the rat SNORF11 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF11-f (ATCC Accession No. ______ ). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF11 receptor, wherein the human SNORF11 receptor comprises an amino acid sequence identical to the sequence of the human SNORF11 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).

Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF1 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF1 receptor and having a sequence identical to the sequence of the human SNORF1 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF1-f (ATCC Accession No. 203898) or (b) a nucleic acid encoding a rat SNORF1 receptor and having a sequence identical to the sequence of the rat SNORF1 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF1-f (ATCC Accession No. 203897). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF1 receptor, wherein the human SNORF1 receptor comprises an amino acid sequence identical to the sequence of the human SNORF1 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).